Case Page


Case Status:    DISMISSED    
On or around 07/16/2009 (Notice of voluntarily dismissal)

Filing Date: February 23, 2009

According to the complaint, the class seeks injunctive relief to enjoin the consummation of a Tender Offer, announced on February 9, 2009, whereby Roche Holding LTD, through its wholly-owned subsidiary Roche Investments USA Inc. (collectively "Roche" or the "Buyer") has commenced a tender offer to acquire the remaining approximately 44% of Genentech's outstanding shares of common stock that it does not already own for $86.50 per share in cash in a transaction valued at approximately $42 billion (the "Tender Offer"). Alternatively, in the event that the Tender Office is completed, plaintiff seeks to recover damages caused by the breach of fiduciary duties and misleading tender offer materials owed by defendant to the Company's shareholders.

On July 10, 2009, the Plaintiff, pursuant to Fed. R. Civ. P. Rule 41(a)(1), voluntarily dismissed action with prejudice and without costs.


Sector: Healthcare
Industry: Biotechnology & Drugs
Headquarters: United States


Ticker Symbol: DNA
Company Market: New York SE
Market Status: Public (Listed)

About the Company & Securities Data

"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.

In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
COURT: N.D. California
DOCKET #: 09-CV-00785
JUDGE: Hon. Ronald M. Whyte
DATE FILED: 02/23/2009
CLASS PERIOD END: 02/23/2009
  1. Bragar, Wexler & Eagel, P.C. (NY)
    885 Third Avenue, Suite 3040 , Bragar, Wexler & Eagel, P.C. (NY), NY 10022
    212.308.5858 ·
  2. Glancy Binkow & Goldberg LLP (Los Angeles)
    1801 Ave. of the Stars, Suite 311, Glancy Binkow & Goldberg LLP (Los Angeles), CA 90067
    310.201.915 310. 201-916 ·
  3. Harwood Feffer LLP
    488 Madison Avenue 8th Floor, Harwood Feffer LLP, NY 10022
    212.935.7400 212.753.3630 ·
No Document Title Filing Date